Viatris (Nasdaq: VTRS) announced Thursday it has agreed to acquire Pacira BioSciences (Nasdaq: PCRX) for $36.50 per share in cash, an aggregate equity value of $1.65 billion. The deal gives Viatris two marketed, patent-protected non-opioid pain medicines and positions the company as a leader in a category where patients and physicians continue to look for alternatives to opioids.
Pacira’s portfolio rests on EXPAREL, a long-acting local anesthetic used to manage pain after surgery, and ZILRETTA, an extended-release injection for osteoarthritis knee pain. Company materials cite up to a 78% decrease in opioid consumption with EXPAREL, though the release notes the clinical benefit of that reduction was not demonstrated. Over the twelve months ended June 30, 2026, Pacira generated about $746 million in revenue and $177 million in adjusted EBITDA. On equity value alone, the price works out to roughly 2.2 times revenue and 9.3 times adjusted EBITDA. GAAP net income over the same period was a much smaller $14.6 million, reflecting significant amortization of acquired intangibles and stock-based compensation.
Viatris says the acquisition advances its push to build an innovative medicines business, and that the products complement its fast-acting meloxicam opportunity in pain. The company also gains Pacira’s U.S. commercial, market access, medical affairs, and research capabilities, along with a pipeline led by a Phase 2 gene therapy candidate for knee osteoarthritis. Viatris plans to apply its expertise in intellectual property and product lifecycle management to extend the portfolio’s reach, including across select international markets where it already operates.
Viatris expects to fund the deal primarily from excess cash, with the remainder from short-term borrowings, and says the impact on its gross leverage ratio will be minimal. The transaction is expected to be immediately accretive to its financial guidance metrics. It will be structured as a tender offer followed by a second-step merger at the same price, with both boards having unanimously approved and Pacira’s board recommending that shareholders tender. Closing requires that a majority of Pacira’s outstanding shares be tendered and that the regulatory waiting period expire, and is expected by the end of 2026. Once complete, Pacira will be delisted from Nasdaq. Viatris will discuss the transaction when it reports third-quarter results on November 5.
Pacira’s leadership said the company has helped nearly 20 million patients access non-opioid pain management and that Viatris’ scale and resources will help bring its therapies to more patients.
The thesis behind the deal is worth examining. Viatris highlighted its record of sustaining sales after competition arrives, a reminder that protected products do not stay protected forever and that part of what Viatris is paying for is its ability to manage that transition.
For small and microcap investors, the takeaway is that commercial-stage healthcare companies with profitable, differentiated products are drawing strategic interest at disciplined valuations. Roughly nine times adjusted EBITDA on equity value is a useful benchmark for smaller specialty pharma and medical technology companies with established revenue, and it reinforces a theme running through this year’s healthcare deal activity, including Supernus’s merger with Indivior and MiMedx’s acquisition of Sanara MedTech. Companies still in development are a different proposition, since their deal values depend far more on clinical milestones than on current earnings.
